All In Biotech

NDA 021870 · Feinstein

Fludeoxyglucose F18

Fludeoxyglucose F-18 · Intravenous · Radioactive Diagnostic Agent

Last checked: Nov 19, 2026Latest source record: Nov 9, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Aug 19, 2005

Approved uses

1

Original approval plus efficacy supplements

Registered trials

389

27 Phase 3, 75 recruiting

FAERS reports

274

204 serious, 43 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 11, 2019.

Fludeoxyglucose F 18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: Fludeoxyglucose F 18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures ( 1 ). 1.1 Oncology For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 1.2 Cardiology For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. 1.3 Neurology For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. 1.1 Oncology For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 1.2 Cardiology For the identification of left ventricular...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 19, 2005 Original approval · Type 5 - New Formulation or New Manufacturer LetterReviewLabel
2 products under this application
  • FLUDEOXYGLUCOSE F18 · FLUDEOXYGLUCOSE F-18 20-400mCi/ML · INJECTABLE, INTRAVENOUS · Prescription · TE AP
  • FLUDEOXYGLUCOSE F18 · FLUDEOXYGLUCOSE F-18 20-200mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Fludeoxyglucose F-18" as an intervention, any sponsor and status, largest first.

All 389 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • cytokine release syndrome24
  • drug ineffective17
  • nausea16
  • off label use15
  • hypotension13
  • neutropenia13
  • platelet count decreased12
  • pyrexia12
  • rash maculo-papular11
  • bone marrow failure10
  • death10
  • wrong product administered10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20062
20099
20106
20118
201214
20136
20163
20179
20184
20195
202013
202118
202242
202351
202424
202536
202623

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: Feinstein

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.